Log in to your Inderes Free account to see all free content on this page.
Create account

Faron Pharmaceuticals

0.48 EUR

+0.31 %

5,703 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

+0.31 %
-4.01 %
-74.86 %
-76.00 %
-76.28 %
-79.54 %
-86.43 %
-87.73 %
-85.65 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
97.26M EUR
Turnover
225.36K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
12.03.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 12.03.2026

Latest extensive report

Released: 23.08.2022

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.5.
2026

General meeting '26

26.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Frontiers Frontiers | The CXCL9/SPP1 polarity axis in tumor-associated macrophages:... This study addresses the limitations of the traditional M1/M2 binary classification for tumor-associated macrophages (TAMs) in non-small cell lung cancer (NS... And another new one. An even stronger...
9 hours ago
by poiju
26
https://www.nature.com/articles/s41408-026-01479-x Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes This summary paper of over 2,000 stem cell transplant + (Venetoclax + Decitabine) patients tells a grim story and illustrates well...
16 hours ago
by poiju
21
https://www.nature.com/articles/s41419-026-08755-5 SPP1+ macrophage-driven interactions shape the tumor microenvironment in lymph node metastatic acral melanoma A recent SPP1 paper strongly supports the BLAZE case: SPP1 macrophages drive melanoma metastasis while building an immunosuppress...
10 hours ago
by poiju
19
journals.plos.org The role of SPP1 in evaluating the prognosis, immune infiltration, and drug... Background Secretory phosphoprotein 1 (SPP1) has been linked to tumor progression and immune regulation, but its prognostic value, impact on the tumor immune microenvironment (TIME), ...
10 hours ago
by poiju
16
EHA is coming up on June 11–14, and the abstracts will be published on May 12. So, within about two weeks, we should have information on whether any new results from the BEXMAB study might be presented at the congress. According to the clinicaltrials.gov page, the study is expected...
1 hour ago
by jukkamu
15
Same problem for everyone: We need to fix the TME, not the T-cell.
16 hours ago
by poiju
13
Last week, HCM received over 3.5 million shares as repayment for a convertible bond at a price of €0.4516, and in addition, roughly 17 million shares came from the issue at a price of under €0.4, taking the underwriting fee into account. The share price performance looks quite challenging...
17 hours ago
12
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.